
#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 12 months ago Tagged analysis antitrust biologics biosimilars competition economics generics intellectual property law litigation market payment pharmaceutical settlement
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 2 years ago Tagged acquisitions agency analysis antitrust bank financial FinTech merger online banking Reform regulation
U.S. bank mergers are on the rise and so are claims that agencies “rubber stamp” […]
Posted 3 years ago Tagged analysis antitrust cartel collusion compliance data economic manipulation screening
Screening out potential collusion and manipulation is the key to corporations’ antitrust compliance by flagging […]